Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

New This Week On Slingshot Insights SA Premium Service: 10/01/2018

|Includes: Dova Pharmaceuticals, Inc. (DOVA), IOVA, PBYI, SPPI, TGTX
Summary

This week's Marketplace postings include interviews with experts discussing assets from SPPI, IOVA, DOVA, PBYI, and TGTX.

This series of instablog posts will highlight the most recently executed transcripts being added to the “Become the Smart Money” , Slingshot Insights Seeking Alpha Premium service. In these blog posts we will give you a bit more information about the subject matter experts we interviewed, the topics covered, and relevant companies. We hope that these brief overviews, combined with our free content and articles, will display what we believe is the content’s unique value to our members. Please don’t hesitate to directly ask us questions at any time via SeekingAlpha Direct message or email to info@slingshotinsights.com.

Why Do Expert Research?

While many individuals we speak to are unaware of the role expert interviews play for many professional investors, it is a $600mm industry. Many funds pay in excess of $100,000 a year just for a relationship with an expert network and over a thousand dollars per call. While these numbers sound staggering, many investors consider them well worth the money. Slingshot Insights’ sharing model has transformed the price of these calls for our customers and now we are making them even more affordable to you on the SeekingAlpha Marketplace for only $75 per month.

Become the newest subscriber to “Become the Smart Money” here and gain access to all of these : Link

Transcript 1: Another View: Discussing TG Therapeutics' Umbralisib and the potential of Pi3K pathway in treating CLL with a doctor in community practice

Ticker: TGTX

Who's the Expert?

  • Medical Oncologist at Chesapeake Oncology Hematology Associates in Maryland; Single specialty Hematology- Oncology group practice.
  • Currently manages 60- 65 patients with CLL.
  • Member of the Maryland State Council on Cancer Control (Council) and Chair Panel A - Maryland Board Of Physicians (MDBOP); fellowship trained at Georgetown.

Interview Goal: This call with focus on the UNITY-CLL trial in both front line and relapse/refractory CLL.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 2: Discussing Puma Bio's NERLYNX (neratinib) for HER2-positive Breast Cancer with a prescribing physician in the community setting

Ticker: PBYI

Who's the Expert?

  • Medical Oncologist who is board certified in internal medicine and medical oncology and hematology in multi-speciality private practice including urology and oncology.
  • Actively manages 75 patients (total) with breast cancer, and 10-15 patients with RCC a month.
  • Has more than 20 peer-reviewed articles in the field of oncology and has presented in national and international conferences including ACP, ASCO, SGIM and ASH; specializes in treating patients with all types of cancer including lung, gastrointestinal, breast, genitourinary (bladder, prostate, renal), skin, myeloma, lymphomas and other blood disorders.

Interview Goal:

Understanding the market potential in the adjuvant therapy setting for NERLYNX. The conversation will focus on the drug's safety profile and efficacy based upon clinical experience with the drug.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 3: Understanding The Standard Of Care, Current Treatment Paradigm And The Unmet Need In Treating Squamous Cell Carcinoma Of The Head And Neck With A Focus On IOVA's LN-145

Ticker: IOVA

Who's the Expert?

  • Medical Oncologist who is board certified in internal medicine and medical oncology and hematology in multi-speciality private practice including urology and oncology.
  • Actively manages 75 patients (total) with breast cancer, and 10-15 patients with RCC a month.
  • Has more than 20 peer-reviewed articles in the field of oncology and has presented in national and international conferences including ACP, ASCO, SGIM and ASH; specializes in treating patients with all types of cancer including lung, gastrointestinal, breast, genitourinary (bladder, prostate, renal), skin, myeloma, lymphomas and other blood disorders.

Interview Goal:

To better understand the disease progression, unmet need, and where Iovance's LN-145, an autologous tumor infiltrating lymphocyte could fit in the treatment landscape.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 4:A look at Dova's avatrombopag (DOPTELET) in treating immune thrombocytopenia purpura

Ticker: DOVA

Who's the Expert?

  • Benign Hematologist (Private NY Practice) & Assistant Professor of Clinical Medicine at Icahn School of Medicine at Mount Sinai.
  • Currently manage 20 patients with ITP.
  • Over 20 years of experience with a clinical focus on immune thrombocytopenia; very familiar with the literature on avatrombopag and Tavalisse.

Interview Goal:

To discuss the market potential of avatrombopag (DOPTELET), an orally administered TPO receptor in development by Dova Pharma in treating ITP.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 5: Another View: Understanding the disease, standard of care, current treatment paradigm and the unmet need in treating squamous cell carcinoma of the head and neck

Ticker: IOVA

Who's the Expert?

  • Assistant Professor, University of Washington School of Medicine & medical oncologist at Seattle Cancer Care Alliance who specializes in treating lung and head and neck cancers.
  • Manages approximately 30 patients with HNSCC and 30 patients with SCLC each month.
  • Has been involved in numerous lung cancer clinical trials and research focuses on designing and implementing clinical trials that test new treatments in the battle against cancer.

Interview Goal:

To get a better understanding of the current treatment paradigm for HNSCC. This call will additionally discuss LN-145, an autologous tumor infiltrating lymphocyte in development by Iovance.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 6: An Expert Call From Our Archives - Preparing For The Upcoming World Lung Conference Abstract Release On September 5th 2018

Ticker: SPPI

Who's the Expert?

  • Director of CU Cancer Center Thoracic Oncology Research Initiative.
  • Lab focused on studying oncogene-addicted cancers to identify novel therapeutic approaches as well as intrinsic and acquired mechanisms of resistance to targeted therapies.
  • PI on a number of clinical trials that focus on oncogene-targeted therapy for lung and other cancers

Interview Goal:

This conversation discussed what to expect in abstract release ahead of the September 2018 World Lung conference.

Link to original project page on Slingshot Insights with questions asked: link

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.